Abstract
10127Background: Regorafenib (REG) is an oral multikinase inhibitor with survival benefit in salvage line therapy for metastatic colorectal cancer (mCRC); fatigue and malaise which are common adver...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have